In 353 JAK inhibitor-naïve myelofibrosis patients, adding selinexor to ruxolitinib raised week-24 SVR35 (49.8% vs 28.0%) but missed the symptom-score coprimary end point. Grade ≥3 adverse events were more frequent (70.1% vs 50.0%).
RCTn = 353
Bose et al. Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial